CBI team arrests Joint Drug Controller for accepting bribe from a private company director

New Delhi: The Central Bureau of Investigation has apprehended a Joint Drug Controller (JDC), posted at CDSCO (Central Drugs Standard Control Organisation()Headquarters, New Delhi and a director of private company based at Delhi in an alleged bribery of Rs. four lakh.

A case was registered against a Joint Drug Controller (India) (JDC), CDSCO Headquarters, New Delhi and others including Directors, Associate Vice President & Head-National Regulatory Affairs (NRA) of separate private companies, two based at New Delhi and another at Bengaluru; Assistant Drug Inspector (ADI), CDSCO, New Delhi and other unknown officials of CDSCO. It was alleged in FIR that the accused was trying to exert undue influence on officers of CDSCO under Directorate General of Health Services. It is alleged that influence was for waiving the Phase III trial of “Insulin Aspart Injection” and the accused agreed to pay bribe amount of Rs.9,00,000/- to JDC for favorably processing the said three files related to private company based at Bangalore and also for favourably recommending the file of “Insulin Aspart injection” to the Subject Expert Committee (SEC) meeting.

In fact, CBI had laid a trap wherein the JDC of CDSCO was caught while accepting bribe of Rs. 4,00,000/- from the Director of Delhi based private company and meanwhile, the said Director of Delhi based private company was also caught with Drug Controller.

Related Posts

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’